Innovita Biological Technology Co. Ltd. A Total Liabilities
Innovita Biological Technology Co. Ltd. A total liabilities. Based on the latest financial reports, Innovita Biological Technology Co. Ltd. A (688253) has total liabilities worth CN¥136.00 Million CNY (≈ $19.90 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Innovita Biological Technology Co. Ltd. (688253) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Innovita Biological Technology Co. Ltd. A (2020–2025)
Total liabilities of Innovita Biological Technology Co. Ltd. A from 2020 to 2025. This chart illustrates how Innovita Biological Technology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
Innovita Biological Technology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Innovita Biological Technology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Genertec Universal Medical Group Company Limited
F:5UM
|
Germany | €59.28 Billion |
|
Altri SGPS SA
LS:ALTR
|
Portugal | €833.58 Million |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
China | CN¥6.70 Billion |
|
Allied Machinery Co. Ltd.
SHG:605060
|
China | CN¥546.67 Million |
|
Zhuzhou Huarui Precision Cutting Tools Co Ltd
SHG:688059
|
China | CN¥1.06 Billion |
|
CSG Holding Co Ltd
SHE:000012
|
China | CN¥18.23 Billion |
|
Welspun Enterprises Limited
NSE:WELENT
|
India | Rs35.17 Billion |
|
China Harzone Industry Corp Ltd
SHE:300527
|
China | CN¥762.17 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Innovita Biological Technology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Innovita Biological Technology Co. Ltd. total assets.
Liquidity & Leverage Metrics
Innovita Biological Technology Co. Ltd. A Total Liabilities Ratios Explained
Innovita Biological Technology Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovita Biological Technology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovita Biological Technology Co. Ltd. A (2020–2025)
The table below shows the annual total liabilities of Innovita Biological Technology Co. Ltd. A from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥223.32 Million ≈ $32.68 Million |
+1.94% |
| 2024-12-31 | CN¥219.07 Million ≈ $32.06 Million |
-2.05% |
| 2023-12-31 | CN¥223.65 Million ≈ $32.73 Million |
-11.69% |
| 2022-12-31 | CN¥253.24 Million ≈ $37.06 Million |
+324.16% |
| 2021-12-31 | CN¥59.70 Million ≈ $8.74 Million |
-47.67% |
| 2020-12-31 | CN¥114.08 Million ≈ $16.69 Million |
-- |
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.